Effect of dapagliflozin in dapa-hf according to background glucose-lowering therapy

Kieran F. Docherty; Pardeep S. Jhund; Olof Bengtsson; David L. Demets; Silvio E. Inzucchi; Lars Køber; Mikhail N. Kosiborod; Anna Maria Langkilde; Felipe A. Martinez; Marc S. Sabatine; Mikaela Sjöstrand; Scott D. Solomon; John J.V. McMurray; the DAPA-HF Investigators and Committees

doi:10.2337/dc20-1402

Effect of dapagliflozin in dapa-hf according to background glucose-lowering therapy

Kieran F. Docherty, Pardeep S. Jhund, Olof Bengtsson, David L. Demets, Silvio E. Inzucchi, Lars Køber, Mikhail N. Kosiborod, Anna Maria Langkilde, Felipe A. Martinez, Marc S. Sabatine, Mikaela Sjöstrand, Scott D. Solomon, John J.V. McMurray^*, the DAPA-HF Investigators and Committees

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

23 Citationer (Scopus)

Abstract

OBJECTIVE To determine whether the benefits of dapagliflozin in patients with heart failure and reduced ejection fraction (HFrEF) and type 2 diabetes in the Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure trial (DAPA-HF) varied by background glucose-lowering therapy (GLT). RESEARCH DESIGN AND METHODS We examined the effect of study treatment by the use or not of GLT and by GLT classes and combinations. The primary outcome was a composite of worsening heart failure (hospitalizationorurgentvisitrequiringintravenoustherapy)orcardiovasculardeath. RESULTS In the 2,139 type 2 diabetes patients, the effect of dapagliflozin on the primary outcome was consistent by GLT use or no use (hazard ratio 0.72 [95% CI 0.58–0.88] vs. 0.86 [0.60–1.23]; interaction P = 0.39) and across GLT classes. CONCLUSIONS In DAPA-HF, dapagliflozin improved outcomes irrespective of use or no use of GLT or by GLT type used in patients with type 2 diabetes and HFrEF.

Originalsprog	Engelsk
Tidsskrift	Diabetes Care
Vol/bind	43
Udgave nummer	11
Sider (fra-til)	2878-2881
Antal sider	4
ISSN	0149-5992
DOI	https://doi.org/10.2337/dc20-1402
Status	Udgivet - 2020

Adgang til dokumentet

10.2337/dc20-1402

https://europepmc.org/articles/pmc7809714?pdf=renderLicens: Andet

Citationsformater

Docherty, K. F., Jhund, P. S., Bengtsson, O., Demets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Sabatine, M. S., Sjöstrand, M., Solomon, S. D., McMurray, J. J. V., & the DAPA-HF Investigators and Committees (2020). Effect of dapagliflozin in dapa-hf according to background glucose-lowering therapy. Diabetes Care, 43(11), 2878-2881. https://doi.org/10.2337/dc20-1402

Docherty, KF, Jhund, PS, Bengtsson, O, Demets, DL, Inzucchi, SE, Køber, L, Kosiborod, MN, Langkilde, AM, Martinez, FA, Sabatine, MS, Sjöstrand, M, Solomon, SD, McMurray, JJV & the DAPA-HF Investigators and Committees 2020, 'Effect of dapagliflozin in dapa-hf according to background glucose-lowering therapy', Diabetes Care, bind 43, nr. 11, s. 2878-2881. https://doi.org/10.2337/dc20-1402

@article{76bd4fbc1ee04ebf91e42997e4b351c8,

title = "Effect of dapagliflozin in dapa-hf according to background glucose-lowering therapy",

abstract = "OBJECTIVE To determine whether the benefits of dapagliflozin in patients with heart failure and reduced ejection fraction (HFrEF) and type 2 diabetes in the Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure trial (DAPA-HF) varied by background glucose-lowering therapy (GLT). RESEARCH DESIGN AND METHODS We examined the effect of study treatment by the use or not of GLT and by GLT classes and combinations. The primary outcome was a composite of worsening heart failure (hospitalizationorurgentvisitrequiringintravenoustherapy)orcardiovasculardeath. RESULTS In the 2,139 type 2 diabetes patients, the effect of dapagliflozin on the primary outcome was consistent by GLT use or no use (hazard ratio 0.72 [95% CI 0.58–0.88] vs. 0.86 [0.60–1.23]; interaction P = 0.39) and across GLT classes. CONCLUSIONS In DAPA-HF, dapagliflozin improved outcomes irrespective of use or no use of GLT or by GLT type used in patients with type 2 diabetes and HFrEF.",

author = "Docherty, {Kieran F.} and Jhund, {Pardeep S.} and Olof Bengtsson and Demets, {David L.} and Inzucchi, {Silvio E.} and Lars K{\o}ber and Kosiborod, {Mikhail N.} and Langkilde, {Anna Maria} and Martinez, {Felipe A.} and Sabatine, {Marc S.} and Mikaela Sj{\"o}strand and Solomon, {Scott D.} and McMurray, {John J.V.} and {the DAPA-HF Investigators and Committees}",

year = "2020",

doi = "10.2337/dc20-1402",

language = "English",

volume = "43",

pages = "2878--2881",

journal = "Diabetes Care",

issn = "0149-5992",

publisher = "American Diabetes Association",

number = "11",

}

TY - JOUR

T1 - Effect of dapagliflozin in dapa-hf according to background glucose-lowering therapy

AU - Docherty, Kieran F.

AU - Jhund, Pardeep S.

AU - Bengtsson, Olof

AU - Demets, David L.

AU - Inzucchi, Silvio E.

AU - Køber, Lars

AU - Kosiborod, Mikhail N.

AU - Langkilde, Anna Maria

AU - Martinez, Felipe A.

AU - Sabatine, Marc S.

AU - Sjöstrand, Mikaela

AU - Solomon, Scott D.

AU - McMurray, John J.V.

AU - the DAPA-HF Investigators and Committees

PY - 2020

Y1 - 2020

N2 - OBJECTIVE To determine whether the benefits of dapagliflozin in patients with heart failure and reduced ejection fraction (HFrEF) and type 2 diabetes in the Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure trial (DAPA-HF) varied by background glucose-lowering therapy (GLT). RESEARCH DESIGN AND METHODS We examined the effect of study treatment by the use or not of GLT and by GLT classes and combinations. The primary outcome was a composite of worsening heart failure (hospitalizationorurgentvisitrequiringintravenoustherapy)orcardiovasculardeath. RESULTS In the 2,139 type 2 diabetes patients, the effect of dapagliflozin on the primary outcome was consistent by GLT use or no use (hazard ratio 0.72 [95% CI 0.58–0.88] vs. 0.86 [0.60–1.23]; interaction P = 0.39) and across GLT classes. CONCLUSIONS In DAPA-HF, dapagliflozin improved outcomes irrespective of use or no use of GLT or by GLT type used in patients with type 2 diabetes and HFrEF.

AB - OBJECTIVE To determine whether the benefits of dapagliflozin in patients with heart failure and reduced ejection fraction (HFrEF) and type 2 diabetes in the Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure trial (DAPA-HF) varied by background glucose-lowering therapy (GLT). RESEARCH DESIGN AND METHODS We examined the effect of study treatment by the use or not of GLT and by GLT classes and combinations. The primary outcome was a composite of worsening heart failure (hospitalizationorurgentvisitrequiringintravenoustherapy)orcardiovasculardeath. RESULTS In the 2,139 type 2 diabetes patients, the effect of dapagliflozin on the primary outcome was consistent by GLT use or no use (hazard ratio 0.72 [95% CI 0.58–0.88] vs. 0.86 [0.60–1.23]; interaction P = 0.39) and across GLT classes. CONCLUSIONS In DAPA-HF, dapagliflozin improved outcomes irrespective of use or no use of GLT or by GLT type used in patients with type 2 diabetes and HFrEF.

U2 - 10.2337/dc20-1402

DO - 10.2337/dc20-1402

M3 - Journal article

C2 - 33082245

AN - SCOPUS:85093854371

SN - 0149-5992

VL - 43

SP - 2878

EP - 2881

JO - Diabetes Care

JF - Diabetes Care

IS - 11

ER -